Scholar Rock OKd to Initiate Phase 2 for Obesity Treatment

 

• Randomized Phase 2 proof-of-concept trial with apitegromab in patients with obesity on GLP-1 therapies on track to initiate mid-2024
• Study aims to show the importance of selective myostatin inhibition in preservation of lean muscle mass as part of healthy, safe weight loss management
• Scholar Rock is also developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity

https://www.biospace.com/article/releases/scholar-rock-announces-fda-clearance-of-ind-application-to-initiate-phase-2-proof-of-concept-trial-with-apitegromab-to-treat-obesity/